Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-05-14 Purchase |
2024-05-15 07:17 am |
BIOCRYST PHARMACEUTICALS INC | BCRX | Thackray Helen M. Chief R&D Officer |
30,000 | $5.86 | $175,800 | 272,139 (Direct) |
View |
| 2024-02-12 Sale |
2024-02-12 4:47 pm |
ImmunoGen Inc. | IMGN | Thackray Helen M. Director |
3,074 | $0 | $0 | 0 (Direct) |
View |
| 2023-04-03 Sale |
2023-04-05 4:33 pm |
BIOCRYST PHARMACEUTICALS INC | BCRX | Thackray Helen M. Chief R&D Officer |
7,000 | $8.29 | $58,030 | 207,275 (Direct) |
View |
| 2022-12-15 Sale |
2022-12-19 4:58 pm |
BIOCRYST PHARMACEUTICALS INC | BCRX | Thackray Helen M. Chief R&D Officer |
3,125 | $10.89 | $34,031 | 133,275 (Direct) |
View |
| 2022-04-01 Sale |
2022-04-04 4:32 pm |
BIOCRYST PHARMACEUTICALS INC | BCRX | Thackray Helen M. Chief R&D Officer |
7,600 | $16.2 | $123,120 | 136,400 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-03-31 Tax Withholding |
2025-04-02 4:18 pm |
N/A N/A |
BIOCRYST PHARMACEUTICALS INC | BCRX | Thackray Helen M. Chief R&D Officer |
7,525 | $7.5 | 377,318 (Direct) |
View |
| 2024-12-19 Option Award |
2024-12-23 4:15 pm |
2025-12-19 2034-12-19 |
BIOCRYST PHARMACEUTICALS INC | BCRX | Thackray Helen M. Chief R&D Officer |
386,900 | $0 | 645,793 (Direct) |
View |
| 2024-12-19 Tax Withholding |
2024-12-23 4:15 pm |
N/A N/A |
BIOCRYST PHARMACEUTICALS INC | BCRX | Thackray Helen M. Chief R&D Officer |
6,096 | $7.39 | 645,793 (Direct) |
View |
| 2024-12-14 Tax Withholding |
2024-12-17 4:03 pm |
N/A N/A |
BIOCRYST PHARMACEUTICALS INC | BCRX | Thackray Helen M. Chief R&D Officer |
7,150 | $7.53 | 264,989 (Direct) |
View |
| 2024-03-31 Tax Withholding |
2024-04-02 4:21 pm |
N/A N/A |
BIOCRYST PHARMACEUTICALS INC | BCRX | Thackray Helen M. Chief R&D Officer |
7,525 | $5.08 | 242,139 (Direct) |
View |
| 2023-12-29 Option Award |
2024-01-03 5:42 pm |
N/A N/A |
ImmunoGen Inc. | IMGN | Thackray Helen M. Director |
252 | $29.65 | 3,074 (Direct) |
View |
| 2023-12-19 Tax Withholding |
2023-12-20 4:42 pm |
N/A N/A |
BIOCRYST PHARMACEUTICALS INC | BCRX | Thackray Helen M. Chief R&D Officer |
5,580 | $6.05 | 249,664 (Direct) |
View |
| 2023-12-14 Option Award |
2023-12-18 4:47 pm |
2024-12-14 2033-12-14 |
BIOCRYST PHARMACEUTICALS INC | BCRX | Thackray Helen M. Chief R&D Officer |
289,000 | $0 | 493,244 (Direct) |
View |
| 2023-12-14 Tax Withholding |
2023-12-18 4:47 pm |
N/A N/A |
BIOCRYST PHARMACEUTICALS INC | BCRX | Thackray Helen M. Chief R&D Officer |
3,031 | $6.43 | 493,244 (Direct) |
View |
| 2023-09-29 Option Award |
2023-10-02 5:07 pm |
N/A N/A |
ImmunoGen Inc. | IMGN | Thackray Helen M. Director |
472 | $15.87 | 2,822 (Direct) |
View |
| 2023-06-30 Option Award |
2023-07-05 5:52 pm |
N/A N/A |
ImmunoGen Inc. | IMGN | Thackray Helen M. Director |
397 | $18.87 | 2,350 (Direct) |
View |
| 2023-06-14 Option Award |
2023-06-16 4:50 pm |
N/A N/A |
ImmunoGen Inc. | IMGN | Thackray Helen M. Director |
32,687 | $0 | 32,687 (Direct) |
View |
| 2023-03-31 Option Award |
2023-04-04 4:54 pm |
N/A N/A |
ImmunoGen Inc. | IMGN | Thackray Helen M. Director |
1,953 | $3.84 | 1,953 (Direct) |
View |
| 2022-12-19 Option Award |
2022-12-21 4:41 pm |
2023-12-19 2032-12-19 |
BIOCRYST PHARMACEUTICALS INC | BCRX | Thackray Helen M. Chief R&D Officer |
319,000 | $0 | 452,275 (Direct) |
View |
| 2022-06-15 Option Award |
2022-06-17 4:09 pm |
N/A N/A |
ImmunoGen Inc. | IMGN | Thackray Helen M. Director |
10,932 | $0 | 72,998 (Direct) |
View |
| 2022-06-15 Option Award |
2022-06-17 4:09 pm |
N/A 2032-06-15 |
ImmunoGen Inc. | IMGN | Thackray Helen M. Director |
32,066 | $3.37 | 72,998 (Direct) |
View |
| 2021-12-14 Option Award |
2021-12-16 5:06 pm |
2022-12-14 2031-12-14 |
BIOCRYST PHARMACEUTICALS INC | BCRX | Thackray Helen M. Chief R&D Officer |
249,000 | $0 | 349,000 (Direct) |
View |
| 2021-09-22 Option Award |
2021-09-23 4:35 pm |
N/A 2031-09-22 |
ImmunoGen Inc. | IMGN | Thackray Helen M. Director |
44,000 | $5.97 | 74,000 (Direct) |
View |
| 2021-09-22 Option Award |
2021-09-23 4:35 pm |
N/A N/A |
ImmunoGen Inc. | IMGN | Thackray Helen M. Director |
30,000 | $0 | 74,000 (Direct) |
View |
| 2021-03-31 Option Award |
2021-04-02 5:26 pm |
2022-03-31 2031-03-31 |
BIOCRYST PHARMACEUTICALS INC | BCRX | Thackray Helen M. Chief R&D Officer |
500,000 | $0 | 500,000 (Direct) |
View |
| 2021-01-20 Option Award |
2021-01-22 4:05 pm |
N/A 2031-01-19 |
GLYCOMIMETICS INC | GLYC | Thackray Helen M. SVP Clinical Development, CMO |
103,500 | $0 | 252,115 (Direct) |
View |
| 2020-05-12 Option Award |
2020-05-14 4:36 pm |
2021-05-12 2030-05-12 |
BIOCRYST PHARMACEUTICALS INC | BCRX | Thackray Helen M. Director |
40,000 | $0 | 40,000 (Direct) |
View |